Kaplan-Meier analysis of the OS and DFS in patients with AML, younger than 60, and with intermediate-risk cytogenetics.

(A) Distribution of the mutant/wt allelic ratio and risk groups defined. (B) OS and (C) DFS for patients with a mutant/wt ratio below (group A) or above (group B) the median of 0.78 compared to FLT3-ITD–negative patients (group C). (D) DFS for patients with a mutant/wt ratio 0.37 or lower (group 1), 0.37 to 0.95 (group 2), and greater than 0.95 (group 3) compared with FLT3-ITD–negative patients (group 4).